| 1.15 0.03 (2.68%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.51 | 1-year : | 1.77 |
| Resists | First : | 1.29 | Second : | 1.51 |
| Pivot price | 1.13  |
|||
| Supports | First : | 0.93 | Second : | 0.77 |
| MAs | MA(5) : | 1.14  |
MA(20) : | 1.16 |
| MA(100) : | 1.56 |
MA(250) : | 1.84 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 49.5 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 3.2 | Low : | 0.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TELA ] has closed below upper band by 41.1%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.2 |
| Low: | 1.1 - 1.11 | 1.11 - 1.12 |
| Close: | 1.11 - 1.12 | 1.12 - 1.13 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Fri, 28 Nov 2025
TELA Bio, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Tue, 25 Nov 2025
TELA Bio Set to Spotlight Soft-Tissue Innovations at Major Healthcare Conference - MyChesCo
Tue, 25 Nov 2025
TELA Bio Unveils New Wave of Hiring With Stock Grants Tied to Growth Push - MyChesCo
Wed, 19 Nov 2025
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - Sahm
Mon, 17 Nov 2025
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Fri, 14 Nov 2025
Citizens Maintains TELA Bio (TELA) Market Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 69 (%) |
| Shares Short | 485 (K) |
| Shares Short P.Month | 365 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | -54.2 % |
| Operating Margin | -45 % |
| Return on Assets (ttm) | -36.5 % |
| Return on Equity (ttm) | -676.5 % |
| Qtrly Rev. Growth | 25.5 % |
| Gross Profit (p.s.) | 1.28 |
| Sales Per Share | 1.9 |
| EBITDA (p.s.) | -0.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -1.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.59 |
| Price to Sales | 0.6 |
| Price to Cash Flow | -1.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|